Biomarker Analysis in Samples Collected during Bronchoscopy in Patients with Dysplasia

Inclusion Criteria

• Individuals identified through the Specialized Programs of Research Excellence (SPORE) Tissue Procurement Screening Project with moderate or severe dysplasia
• Patients identified by private and academic physicians with moderate or severe dysplasia on cytology
• One year or greater survivors of one or more aerodigestive system carcinomas
• Patients with head and neck cancers who are undergoing routine panendoscopy
• Patients undergoing resection of a bronchogenic carcinoma
• Fully resected stage I non-small cell cancer patients
• Patients undergoing bronchoscopy for diagnosis or staging of suspected lung cancer
• Subjects with previous high-grade dysplasia or worse undergoing subsequent bronchoscopy for surveillance or monitoring of response to endobronchial treatment
• Patients suspected of or at risk for neoplastic lung disease who are undergoing a bronchoscopy in which differential diagnostic considerations may include multiple other etiologies such as infection and other processes

Exclusion Criteria

• Clinically apparent bleeding diathesis
• Cardiac dysrhythmia that is potentially life threatening, such as ventricular tachycardia, multifocal premature ventricular contractions or supraventricular tachycardias with a rapid ventricular response. Well-controlled atrial fibrillation or rare (< 2/minute) premature ventricular contractions are not exclusionary
• Hypoxemia (less than 90% saturation with supplemental oxygen) prior to bronchoscopy
• Evidence of clinically active coronary artery disease, including myocardial infarction within 6 weeks, anginal chest pain, or poorly controlled congestive heart failure, or any other serious medical condition which would preclude a patient from undergoing a bronchoscopy
• Acute bronchitis or pneumonia within 8 weeks, except if these are considered clinically to be possibly a result of lung cancer
• Inability to give informed consent
• Normal volunteers who have lung disease, asthma, a respiratory illness in the two weeks prior to enrollment, or a known bleeding disorder